CooperVision’s Brilliant Futures™ Myopia Management Program Expands Globally
Friday, December 4 2020 | 10 h 29 min | News, Press Release
Less than a year after debuting its Brilliant Futures™ Myopia Management Program featuring the MiSight® 1 day contact lens in the United States, CooperVision is now expanding the comprehensive approach to multiple countries, including the United Kingdom, Russia, Spain, Portugal, Canada, South Korea, and Taiwan. This seeks to create a new standard of care by creating the optimal environment for compliance, satisfaction, clinical outcomes and long-term loyalty.
“Several years from now, I believe we will look back at late 2020 as an inflection point in the global myopia management movement,” said Dan McBride, President of CooperVision. “Never before has there been this degree of momentum, driven in large part by substantial investments CooperVision is making in evidence-based science, innovative products, and comprehensive clinical and practice management education in the form of Brilliant Futures™. Partnering with the optometry, ophthalmology and pediatric health communities, we have a real opportunity to change the lives of countless children in the decades ahead.”
Brilliant Futures™ is now coming to countries where MiSight® 1 day has been previously available, such as the United Kingdom in October. Indie Grewal, Optometrist and President of the British Contact Lens Association (BCLA), says myopia management “has the potential to revolutionize clinical outcomes and can allow us to change the trajectory of childhood myopia in practice.”
In Canada, where MiSight® 1 day prescribing has steadily grown in recent years, the Brilliant Futures™ program became available last week, A pilot study conducted by the Centre for Ocular Research & Education (CORE), the University of Waterloo’s School of Optometry & Vision Science and the Canadian National Institute for the Blind determined that almost 30% of Canadian children aged 11-13 are myopic.
“We are experiencing a remarkable upturn in acknowledging that simply correcting for myopia is not enough, especially when we now have proven technologies to manage and help control its progression,” said McBride. “There’s still much to be done in establishing myopia management as the standard of care. With advancements such as Brilliant Futures™ and the contributions of other like-minded innovators, healthcare professionals, government officials and professional associations, this goal is clearly within sight.”
Click HERE for the full press release.
